Deciphera Pharmaceuticals Email Format

Pharmaceutical Manufacturing
201-500 employees
Waltham, MA, USA

Deciphera Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing innovative kinase inhibitor medicines to improve the lives of people with cancer.

Find contacts at Deciphera Pharmaceuticals

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@deciphera.com

Company Overview

Industry
Pharmaceutical Manufacturing
Founded
2003
Headquarters
Waltham, MA, USA
Revenue
$100M+
FUNDING Stage
Public
Key Executives
Ryota Udagawa (President & Chief Executive Officer), Jenn Larson (Senior Vice President and Chief Financial Officer), Margarida Duarte (Executive Vice President, Global Chief Commercial Officer)

Tech Stack

Adobe Analytics

Analytics

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals uses the first.last format, so Jane Smith would be jane.smith@deciphera.com.

What approved cancer medicines does Deciphera Pharmaceuticals currently commercialize?

Deciphera Pharmaceuticals commercializes QINLOCK (ripretinib) for advanced gastrointestinal stromal tumor and ROMVIMZA (vimseltinib) for tenosynovial giant cell tumor, with tirabrutinib under FDA review for relapsed or refractory primary central nervous system lymphoma as of 2026.

How does Deciphera Pharmaceuticals use its switch-control kinase inhibitor platform to build its pipeline?

Deciphera Pharmaceuticals uses its proprietary switch-control kinase inhibitor discovery platform to design drugs that target kinase enzymes driving cancer growth and resistance, producing a pipeline spanning GIST, TGCT, PCNSL, polycythemia vera, and several other oncology indications.

Who leads Deciphera Pharmaceuticals as CEO in 2026?

Ryota Udagawa serves as President and Chief Executive Officer of Deciphera Pharmaceuticals in 2026, with Jenn Larson as Chief Financial Officer and Margarida Duarte as Global Chief Commercial Officer.

Can Clay help me find a verified Deciphera Pharmaceuticals contact email?

Yes, Clay can verify and enrich contact records for Deciphera Pharmaceuticals employees by confirming the first.last@deciphera.com format and surfacing accurate, up-to-date contact details for your outreach or prospect list.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles